- About Us
- Phase I
- Phase II
- Data Services
- Core Laboratories
- Media Center
The University of TexasMD Anderson Cancer Center has formed a research alliance with global pharmaceutical developer GlaxoSmithKline (GSK) to strengthen its efforts in advancing therapies that train the body's immune system to combat cancer.
T1D Exchange, the first program of Unitio, a nonprofit organization that helps build patient community and research platforms dedicated to eradicating chronic diseases such as type 1 diabetes, and Eli Lilly have entered into a research collaboration that will enable both organizations to gain deeper, real-world insight about the experience of people with type 1 diabetes, to identify new ways to improve care and advance outcomes.
PHARMAC has announced its intention to test out a contestable fund for high-cost medicines for rare disorders, which could be seeking proposals from pharmaceutical companies by the end of 2014. Promoting competition among suppliers could be the key to improving patients’ access to high-cost medicines for rare disorders, said chief executive Steffan Crausaz. The fund is a response to concerns about access to these medicines that PHARMAC has been hearing from patients through forums and consultations in recent months.
Clinipace Worldwide, a global digital CRO (dCRO), has announced that Karyopharm Therapeutics, a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, has entered into a preferred provider agreement with Clinipace to manage several clinical programs, including oncology and wound healing.
Greenphire, a provider of payment technology for the clinical trial industry, has formed a strategic partnership with ERT, a global provider of high-quality patient safety and efficacy endpoint data collection. The partnership will integrate Greenphire's ClinCard System with ERT's best-in-class electronic patient reported outcomes (ePRO) technology.
Verified Clinical Trials (VCT) and the Alliance for Clinical Research Excellence and Safety (ACRES) have launched a partnership.
The CEO Roundtable on Cancer has launched Project Data Sphere, a new online oncology data-sharing platform using de-identified cancer patient information with the goal of accelerating drug discovery—by developing more efficient clinical trial protocols, epidemiological studies and, ultimately, new cancer therapies.
Roche has acquired IQuum, a privately held company focused on developing point-of-care offerings for the molecular diagnostics market. Roche will pay IQuum shareholders $275 million upfront and up to $175 million in contingent product-related milestones.
In a meeting at the EMA April 4, the EMA’s executive director, Guido Rasi, and the national manager of the Australian Therapeutic Goods Administration (TGA), John Skerritt, announced the two regulators have agreed to share the full assessment reports related to marketing authorizations of orphan medicines, intended to treat rare diseases.
WaveCheck has received a $100,000 catalyst grant from the Ontario Institute for Cancer Research (OICR). The funding builds upon MaRS Innovation's Indiegogo crowdfunding campaign for WaveCheck, which successfully raised over $50,000 from over 500 supporters worldwide over two months last fall.
The Lieber Institute for Brain Development (LIBD), an independent nonprofit, and pharmaceutical companies Astellas, Eli Lilly, Lundbeck, Pfizer and Roche are participating in an early-stage research consortium to analyze RNA, the genomic and epigenetic data obtained from human brains. The goal of the consortium is to expand knowledge around the genetic contribution to brain disorders in the hope of identifying potential new treatment options.
Daiichi Sankyo and UC San Francisco (UCSF) have established a drug-discovery collaboration focused on developing novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases.
TetraLogic Pharmaceuticals, a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, will acquire Shape Pharmaceuticals, a privately held biotechnology company developing suberohydroxamic acid phenyl ester (SHAPE), a novel, tissue-targeted HDAC inhibitor in a topical gel formulation to treat stage IA-IIA Cutaneous T-Cell Lymphoma (CTCL), adding a second clinical-stage oncology compound to the TetraLogic portfolio.
PatientsLikeMe, a patient network and a real-time research platform, has formed a five-year agreement with Genentech, a member of the Roche Group, to explore using PatientsLikeMe’s global online patient network to develop innovative ways to research patients’ real-world experiences with disease and treatment. The agreement is the first broad research collaboration between PatientsLikeMe and a pharmaceutical company and provides PatientsLikeMe the opportunity to expand its patient network in oncology.
Updated list of approved active moieties to which FDA has issued a Written Request for pediatric studies
Status: Active, not recruiting, Condition Summary: Parkinson Disease; Alzheimer Disease
Status: Active, not recruiting, Condition Summary: Autism Spectrum Disorder; Insomnia
In a quest to cure chronic virological diseases such as HIV, hepatitis B and hepatitis C, Bristol-Myers Squibb has asked European researchers—notably junior faculty and young investigators—to submit innovative research ideas to accelerate novel solutions as part of its Partnering for Cure program.